title: High-dose glibenclamide can replace insulin therapy despite transitory diarrhea in early-onset diabetes caused by a novel R201L Kir6.2 mutation.
authors.forename: Ethel
authors.initials: E
authors.lastname: Codner
authors.forename: Sarah
authors.initials: S
authors.lastname: Flanagan
authors.forename: Sian
authors.initials: S
authors.lastname: Ellard
authors.forename: Hernán
authors.initials: H
authors.lastname: García
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Hattersley
mesh_terms: D019943:Amino Acid Substitution; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003967:Diarrhea / Q000139:chemically induced*; D005260:Female; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007328:Insulin / Q000627:therapeutic use*; D020125:Mutation, Missense; D024661:Potassium Channels, Inwardly Rectifying / Q000235:genetics*; D000099161:Kcnj11 Channel
chemical_list: D005905:Glyburide; D007004:Hypoglycemic Agents; D007328:Insulin; D024661:Potassium Channels, Inwardly Rectifying; D000099161:Kcnj11 Channel